Literature DB >> 10923435

[Hepatitis B virus infection and aflatoxin exposure in the development of primary liver cancer].

P Lu1, S Kuang, J Wang.   

Abstract

OBJECTIVE: To investigate the role of hepatitis B Virus (HBV) infection and aflatoxin (AF) exposure in the development of primary liver cancer (PLC).
METHODS: A 10-year prospective case-control study was carried out in 737 HBsAg carriers and 699 HBsAg negative cases, and the aflatoxin B1 albumin adducts (AFB1-Alb) were detected in the serum of the cohort including 30 HBsAg postive cases and 150 control individuals according to the case-control study model (ratio 1:5) at random in the high prevalance area of PLC.
RESULTS: The average year-incidence rate was significantly higher in the HBsAg postive group (824.13/100,000) than in the control group (70.97/100,000, RR = 11.61). There was no significant difference in the incidence rate of other tumors between the two groups (P > 0.05). The serum positive rate of AFB1-Alb was significantly higher in the PLC group (76.67%) than in the control group (48.67%, OR = 3.47), and the serum concentration of AFB1-Alb was also significantly higher in the PLC group than in the control group (P < 0.01).
CONCLUSION: HBV infection and AF exposure are important etiological factors in the development of PLC and both result in carcinogenic synergy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10923435

Source DB:  PubMed          Journal:  Zhonghua Yi Xue Za Zhi        ISSN: 0376-2491


  2 in total

1.  Effects of long-term tea polyphenols consumption on hepatic microsomal drug-metabolizing enzymes and liver function in Wistar rats.

Authors:  Tao-Tao Liu; Ning-Sheng Liang; Yan Li; Fan Yang; Yi Lu; Zi-Qing Meng; Li-Sheng Zhang
Journal:  World J Gastroenterol       Date:  2003-12       Impact factor: 5.742

Review 2.  Recognition criteria for occupational cancers in relation to hepatitis B virus and hepatitis C virus in Korea.

Authors:  Hogil Kim; Yun Kyung Chung; Inah Kim
Journal:  Ann Occup Environ Med       Date:  2018-01-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.